Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Roque DM, et al. Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10. Am J Obstet Gynecol. 2013. PMID: 23583215
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.
Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD. Carrara L, et al. Among authors: roque dm. Gynecol Oncol. 2012 Apr;125(1):231-6. doi: 10.1016/j.ygyno.2011.12.446. Epub 2011 Dec 29. Gynecol Oncol. 2012. PMID: 22209775 Free PMC article.
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Bellone S, et al. Br J Cancer. 2012 Apr 24;106(9):1543-50. doi: 10.1038/bjc.2012.132. Br J Cancer. 2012. PMID: 22531721 Free PMC article.
Updates in therapy for uterine serous carcinoma.
Roque DM, Santin AD. Roque DM, et al. Curr Opin Obstet Gynecol. 2013 Feb;25(1):29-37. doi: 10.1097/GCO.0b013e32835af98d. Curr Opin Obstet Gynecol. 2013. PMID: 23138439 Review.
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.
Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD. Bignotti E, et al. Among authors: roque dm. BMC Clin Pathol. 2012 Nov 14;12:22. doi: 10.1186/1472-6890-12-22. BMC Clin Pathol. 2012. PMID: 23151048 Free PMC article.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Zhao S, et al. Among authors: roque dm. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Proc Natl Acad Sci U S A. 2013. PMID: 23359684 Free PMC article.
61 results